Femoral vein homograft for neoaortic reconstruction in the Norwood stage 1 operation: A follow-up study  by Seery, Thomas J. et al.
C
H
D
Congenital Heart Disease Seery et alFemoral vein homograft for neoaortic reconstruction in the Norwood
stage 1 operation: A follow-up studyThomas J. Seery, MD,a Pranava Sinha, MD,b David Zurakowski, PhD,c and Richard A. Jonas, MDbFrom th
tional
Surge
Disclosu
Receive
public
Address
hen F
igan A
0022-52
Copyrig
http://dx
550Objective: The aim of this study was to analyze our experience with the cryopreserved femoral vein homograft
in comparison with standard biomaterials for neoaortic reconstruction in the Norwood stage 1 operation.
Methods:All patients who underwent theNorwood operation fromSeptember 2004 toApril 2011were analyzed
retrospectively (n¼ 107). Patients were grouped into groupA (cryopreserved femoral vein homograft; n¼ 72) or
group B (other; n¼ 35). Intergroup comparisons and dimensional analyses of all available angiograms were per-
formed. Two surgical techniques, ‘‘standard homograft cuff’’ and ‘‘homograft tube,’’ were compared.
Results: Multivariable Cox regression analysis revealed use of biomaterial other than femoral vein (P ¼ .01;
hazard ratio, 3.0; 95% confidence interval [CI], 1.4-6.4), weight less than 2.5 kg at the time of stage 1
(P ¼ .01; hazard ratio, 3.7; 95% CI, 1.7-7.8), and need for extracorporeal membrane oxygenator support after
stage 1 (P<.001; hazard ratio, 13.8; 95%CI, 5.9-31.9) as significant independent predictors of overall mortality.
Improved late survival at 48 months was seen with the femoral vein homograft compared with other biomaterials
when a ‘‘homograft tube with end-to-side ascending aortic reimplantation technique’’ was used (group A [75%]
vs group B [44%]; P ¼ .03). With the use of the ‘‘homograft cuff technique,’’ survival was similar for femoral
vein homografts and other biomaterials (group A [67%] vs group B [61%]; P ¼ .85). Similar neoaortic coarc-
tation rates were seen in both groups (A: 25/59 [42%] vs B: 12/26 [46%]; P¼ .81). A progressive increase in the
diameter of the neoaorta was seen over time in both groups with both technical modifications (tube grafts pre–
stage 2 vs pre–stage 3: group A [10.61 mm  1.93 vs 13.74 mm  3.16] [P< .001] and group B [13.93
mm  6.71 vs 17.38 mm  5.92] [P ¼ .049]); cuff repair pre–stage 2 to pre–stage 3: group A [13.98
mm  2.13 vs 19.09 mm  4.18] [P ¼ .002] and group B [16.06 mm  3.05 vs 19.73 mm  2.93]
[P<.001]). The neoaortic Z-scores were generous with the use of homograft cuffs and modest when homograft
tubes were used and maintained in range over the follow-up time.
Conclusions: Survivals are improved with the use of femoral vein homograft for neoaortic reconstruction for
Norwood stage 1 operation, especially when used as a homograft tube with end-to-side aortic reimplantation.
Femoral vein homografts have similar recoarctation rates compared with standard biomaterials. Progressive
growth/dilation of the neoaorta in proportion to somatic growth is seen with femoral vein tube grafts. (J Thorac
Cardiovasc Surg 2013;146:550-6)Aortic or pulmonary homografts are the most commonly
used supplemental biomaterials for neoaortic reconstruc-
tion in the stage 1 Norwood operation. The variable wall
thickness of aortic homografts and the length limitation of
the pulmonary homografts pose technical challenges for
neoaortic reconstruction, especially in patients with a dimin-
utive ascending aorta. Additionally, limited availability of
pediatric aortic and pulmonary homografts and their high
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The Journal of Thoracic and Cardiovascular Surgneoaortic reconstruction for the Norwood stage 1 proce-
dure.1-3 We4 reported the use of cryopreserved femoral
vein homograft as an alternative biomaterial for neoaortic
reconstruction in the stage 1 Norwood operation in 2009.4
This report documents short- to intermediate-term
follow-up.METHODS
Owing to the retrospective nature of the study, the institutional review
board at Children’s National Medical Center approved waiver of docu-
mented consent. All patients who underwent the Norwood stage 1 opera-
tion for hypoplastic left heart syndrome (HLHS) or HLHS variants
between September 2004 and April 2011 were included in the study. The
patients were grouped according to the homograft material used for neo-
aortic reconstruction into group A (femoral vein homograft) and group B
(material other than femoral vein homograft, ie, aortic or pulmonary homo-
graft, autologous pericardium, and prosthetic material). Each group was
further divided into 2 categories by type of repair; standard homograft
cuff technique or circumferential tube homograft (with end-to-side ascend-
ing aortic anastomosis, or without end to side aortic reimplantation or the
‘‘double-barrel’’ technique). Demographic, preoperative, intraoperative,
postoperative, and follow-up data were reviewed.ery c September 2013
Abbreviations and Acronyms
CI ¼ confidence interval
ECMO ¼ extracorporeal membrane oxygenator
HLHS ¼ hypoplastic left heart syndrome
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DOperative Technique
All patients underwent stage 1 Norwood reconstruction via a median
sternotomy, hypothermic low-flow cardiopulmonary bypass, and circula-
tory arrest. A pH-stat strategy, goal hematocrit on bypass of more than
30%, and deep hypothermic circulatory arrest for arch reconstruction
were applied in all patients. The technical aspects of the surgical procedure
are widely described elsewhere.5 It is our preference to use a right ventri-
cle–pulmonary artery conduit as a source for pulmonary blood flow unless
it is technically not feasible (left ventricular morphology of the single ven-
tricle, inaccessible right ventricular infundibulum owing to cardiac posi-
tion, or presence of large coronaries contraindicating a ventriculotomy),
and then a systemic–pulmonary artery shunt is used. Neoaortic reconstruc-
tion was performed using either a homograft cuff or a circumferential
homograft tube. Depending on the size of the ascending aorta, either
end-to-side ascending aortic reimplantation was performed or a homograft
tube was used without end-to-side ascending aortic reimplantation.
Homograft Cuff Technique
After division of the ductus arteriosus at its junction with the descending
aorta, the resulting aortotomy is extended distally onto the descending aorta
for several millimeters and proximally along the undersurface of the aortic
arch, ascending to the level of the divided main pulmonary artery. An anas-
tomosis is fashioned between the proximal portion of the divided mainFIGURE 1. Technical modifications used for neoaortic reconstruction. A, Hom
reimplantation. C, Homograft tube without end-to-side aortic reimplantation, ‘‘d
grams for the 3 techniques. D, Homograft cuff. E, Homograft tube with end-to-s
aortic reimplantation, ‘‘double-barrel.’’ White line depicts sites of angiographic
The Journal of Thoracic and Capulmonary artery and the filleted aorta with a supplementary cuff of homo-
graft (Figure 1, A).
Circumferential Tube Homograft Technique
With end-to-side ascending aortic reimplantation. The
ductus arteriosus is transected at its junction with the descending aorta.
The ascending aorta is divided at its junction with the proximal arch.
The resulting orifice in the proximal arch is extended across the undersur-
face of the aortic arch through the ductal orifice and beyond onto the de-
scending aorta beyond the coarctation shelf. The homograft, beveled
appropriately, is used as a circumferential tube to connect the divided prox-
imal pulmonary artery to the undersurface of the arch and proximal ascend-
ing aorta. With the neoaorta filled with saline, to both deair and distend the
homograft, an appropriate-sized opening is created along the right lateral
aspect of the proximal homograft. The ascending aorta is spatulated and
anastomosed end to side to the homograft tube with interrupted sutures
at the heel and the remainder continuous 7-0 Prolene polypropylene (Ethi-
con, Inc, Somerville, NJ) (Figure 1, B). Creation of a long ascending aortic
anastomosis limits the nongrowing rim to a fewmillimeters at the proximal
and distal homograft tube anastomotic sites only, with the majority of the
homograft circumference still having the growth potential.
Without end-to-side aortic reimplantation, ‘‘double-
barrel.’’ The ‘‘double-barrel’’ technique is suitable for patients with
an ascending aorta larger than 5 mm. Often the arterial cannula is placed
directly into the mid to distal ascending aorta along its right lateral aspect.
After division of the ductus arteriosus, the resulting aortotomy is extended
distally onto the descending aorta. Proximally, the aortotomy is extended
along the undersurface of the aortic arch to the ascending aorta. It is impor-
tant to extend the ascending aortotomy inferiorly beyond the aortic cannu-
lation site to avoid narrowing of the ascending aorta at this level. The
circumferential homograft tube is shaped appropriately and a beveledograft cuff technique. B, Homograft tube with end-to-side ascending aortic
ouble-barrel.’’ Black arrow depicts site of aortic cannulation. Lateral aorto-
ide ascending aortic reimplantation. F, Homograft tube without end-to-side
measurements for each of the techniques.
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Danastomosis is fashioned to the aortotomy. The homograft tube is cut to
length and anastomosed end to end to the proximal divided main pulmo-
nary artery (Figure 1, C).
Angiographic Data
Neoaortic dimensions were estimated from all available angiograms
from all cardiac catheterizations performed (pre–stage 2, pre–stage 3,
and others). The lateral projection of the aortic arch angiogram was used
to measure the diameter of the ascending neoaorta in millimeters
(Figure 1, A to C). To minimize interobserver variability, 2 independent ob-
servers made measurements and the average of the 2 was used for analysis.
Dimensional comparisons were made between group A and group B, as
well as between ‘‘homograft cuffs’’ and ‘‘homograft tubes.’’ Ascending
aortic Z-scores were calculated using standard published data.6
Neoaortic coarctation was defined by the need for intervention owing to
narrowing of the reconstructed aorta (balloon angioplasty or surgical aortic
arch augmentation) at any time during the study period. The criteria for
reintervention at the time of cardiac catheterization were significant angio-
graphic narrowing (coarctation index<0.77) or pressure gradient of more
than 15 mm Hg (mean)8 or more than 20 mm Hg (peak). Surgical arch
augmentation was considered for failed balloon angioplasty or aortic
arch narrowing considered unsuitable for balloon angioplasty.
Statistical Analysis
All continuous data are presented as mean  standard deviation, and
categorical data are presented as number (percentages). Patient survival
was analyzed with the Kaplan-Meier method and groups were compared
using the log–rank test. Cox multivariable regression analysis was used
to determine independent risk factors of mortality with hazard ratios to al-
low for censoring and to adjust for covariates, including biomaterial, pa-
tient weight, and need for support with an extracorporeal membrane
oxygenator (ECMO). Inasmuch as femoral vein homograft recipients
(group A) were the more contemporary patients being compared with his-
torical controls (group B), date of operation was included in the multivari-
able analysis, to account for the ‘‘era effect.’’
Ascending aorta diameter and Z-scores followed a normal Gaussian-
shaped distribution and therefore were compared between femoral vein ho-
mograft and other biomaterial groups using the Student t test. Comparison
of aortic diameter for each group between pre–stage 2 and pre–stage 3
were assessed using paired t tests. Rate of neoaortic coarctation was com-
pared using Fisher’s exact test and logistic regression was applied to identify
predictors of coarctation. The number of operative survivors constituted the
denominator for dimensional and neoaortic coarctation analyses. Statistical
analysiswas performed usingSAS version 9.2 (SAS Institute, Inc,Cary, NC).RESULTS
Between September 2004 and April 2011, a total of 107
patients underwent the Norwood stage 1 procedure. Cryo-
preserved femoral vein homograft was used in 72 patients
(group A), and in 35 patients biomaterials other than femo-
ral vein were used for neoaortic reconstruction (group B)
(31 aortic–pulmonary homograft, 3 autologous pericar-
dium, 1 polytetrafluoroethylene [Gore-Tex; registered
trademark of W. L. Gore & Associates, Inc, Flagstaff,
Ariz). In February 2007, we switched to exclusively using
cryopreserved femoral vein homograft for neoaortic recon-
struction in the Norwood stage 1 operation. All patients who
underwent the procedure between February 2007 and April
2011 received the femoral vein homograft (group A),
whereas before this period (September 2004 and February552 The Journal of Thoracic and Cardiovascular Surg2007) all patients underwent the procedure using other bio-
materials (group B).
The standard homograft cuff techniquewas used in 15 pa-
tients in group A and 18 patients in group B. A total of 48
patients (32 group A, 16 group B) underwent neoaortic re-
construction using a circumferential homograft tube with
end-to-side ascending aortic reimplantation. The majority
of patients (84%) in group A that underwent this technique
had a diminutive ascending aorta (<2 mm). This was also
true in group B (81%). The presence of an adequate-sized
ascending aorta allowed neoaortic reconstruction using
a circumferential homograft tube without end-to-side aortic
reimplantation in 26 patients in group A, whereas this was
the technique used for only 1 of the patients in group B.
The anatomic, preoperative, intraoperative, and postoper-
ative details of all patients are detailed in Tables 1 and 2.
To date, 78 patients have undergone stage 2 (bidirectional
Glenn) and 45 stage 3 (Fontan) procedures.Mortality
There were a total of 22 (20.5%) operative deaths (13 in
group A; 9 in group B), with nonsignificant differences be-
tween the 2 groups (group A, 18.1%; group B, 25.7%;
P¼ .45). Excluding the 4 nonhomograft patients from group
B (3, autologouspericardium; 1, polytetrafluoroethylene) did
not affect the mortality (group A, 18.1%; group B, 25.8%;
P¼ .43). At a median follow-up of 3.4 years (1.6-5.2 years),
therewere 7 late deaths in groupA and 7 in groupB, amount-
ing to an overallmortality of 27.8% in groupA and 45.7% in
group B (P ¼ .08). There were a total of 4 interstage 1-2
deaths (1, group A; 3, group B) and 6 interstage 2-3 deaths
(5, group A; 1, group B). Death after Fontan completion oc-
curred in 4 patients (1, group A; 3, group B) (Table 1).
Multivariable Cox regression analysis revealed the use of
biomaterial other than femoral vein (P ¼ .01; hazard ratio,
3.0; 95% confidence interval [CI], 1.4-6.4), weight less
than 2.5 kg at the time of stage 1 (P ¼ .01; hazard ratio,
3.7; 95% CI, 1.7-7.8), and need for ECMO support after
stage 1 (P< .001, hazard ratio, 13.8; 95% CI, 5.9-31.9)
as significant independent predictors of overall mortality
(Table 3). Improved late survival at 48 months was seen
with the femoral vein homograft compared with other bio-
materials when a ‘‘homograft tube with end-to-side ascend-
ing aortic implantation technique’’ was used (group A
[75%] vs group B [44%]; P¼ .03).With use of ‘‘homograft
cuff technique,’’ survival was similar for femoral vein ho-
mografts and other biomaterials (group A [67%] vs group
B [61%]; P ¼ .85) (Figure 2).Dimensional Analysis
By the end of the study period, a total of 202 cardiac cath-
eterizations had been performed in 71 survivors. These in-
cluded 147 planned (92, pre–stage 2 and 55, pre–stage 3)ery c September 2013
TABLE 1. Comparison of anatomic, preoperative, intraoperative, postoperative, and neoaortic dimensions
Variable Overall (n ¼ 107) Group A (n ¼ 72) Group B (n ¼ 35) P value
Anatomic
Sex
Male 54 (50%) 34 (47%) 20 (57%) —
Female 53 (50%) 38 (53%) 15 (43%) —
Prematurity (<36 wk gestation) 13 (12%) 9 (13%) 4 (11%) —
Weight<2.5 kg 17 (16%) 11 (15%) 6 (17%) —
HLHS 71 (66%) 47 (66%) 24 (69%) —
Aortic atresia/mitral atresia 49 (69%) 32 (68%) 17 (71%) —
Aortic stenosis/mitral stenosis 13 (18%) 10 (21%) 3 (13%) —
Aortic atresia/mitral stenosis 9 (13%) 5 (11%) 4 (16%) —
HLHS variants
DORV 15 (14%) 9 (13%) 6 (17%) —
Unbalanced AVC defect 10 (9%) 8 (11%) 2 (6%) —
Tricuspid atresia 5 (5%) 2 (3%) 3 (9%) —
DILV 5 (5%) 4 (6%) 1 (2%) —
D-TGA 1 (1%) 1 (1%) 0 (0%) —
Single ventricle morphology
Right 99 (92%) 65 (90%) 34 (97%) —
Left 6 (6%) 5 (7%) 1 (3%) —
Ambiguous 2 (2%) 2 (3%) 0 (0%) —
Intact/restrictive interatrial septum 10 (9%) 7 (10%) 3 (9%) —
Diminutive ascending aorta (<2 mm) 42 (39%) 28 (39%) 14 (40%) —
Size (mm) of ascending aorta (mean) 3.7  2.1 3.5  1.9 4.0  2.3 .36
Intraoperative
Technique
Homograft cuff 33 (30%) 15 (20%) 18 (51%) —
Circumferential tube homograft with end-to-side ascending
aortic anastomosis
48 (45%) 32 (44%) 16 (46%) —
Circumferential tube homograft without end-to-side
aortic anastomosis
27 (25%) 26 (36%) 1 (3%) —
RV-PA conduit 94 (88%) 63 (87%) 31 (89%) —
Systemic–PA shunt 13 (12%) 9 (13%) 4 (11%) —
Postoperative
Postoperative ECMO 23 (21%) 16 (22%) 7 (20%) —
Operative mortality 22 (20.5%) 13 (18.1%) 9 (25.7%) .45
Late mortality 13 (12.1%) 7 (9.7%) 7 (20.0%) —
Overall mortality 36 (33.6%) 20 (27.8%) 16 (45.7%) .08
Interstage death (1/ 2) 25 (23.3%) 1 (1.4%) 3 (8.6%) —
Interstage death (2/3) 7 (6.5%) 5 (6.9%) 1 (2.9%) —
Follow-up, y (median) 3.0 (1.8-5.0) 2.2 (1.6-3.0) 5.4 (4.9-6.3) <.001
Neoaortic coarctation
Neoaortic coarctation* 37 (37/85 ¼ 44%) 25 (25/59 ¼ 42%) 12 (12/26 ¼ 46%) .81
Coarctation with circumferential tube homograft 24 (24/57 ¼ 42%) 19 (19/46 ¼ 41%) 5 (5/11 ¼ 45%) 1.00
Coarctation with homograft cuff 13 (13/28 ¼ 46%) 6 (6/13 ¼ 46%) 7 (7/15 ¼ 47%) 1.00
Narrowing distal to LSA 33 (33/37 ¼ 89%) 22 (22/25 ¼ 88%) 11 (11/12 ¼ 92%) 1.00
Narrowing in ascending aorta 7 (7/37 ¼ 19%) 5 (5/25 ¼ 20%) 2 (2/12 ¼ 16%) 1.00
Narrowing distal to LSA and in ascending aorta (at separate times) 3 (3/37 ¼ 8%) 2 (2/25 ¼ 8%) 1 (1/12 ¼ 8%) 1.00
Continuous data are presented as mean  standard deviation, and categorical data presented as number (percentages). HLHS, Hypoplastic left heart syndrome; DORV, double-
outlet right ventricle; AVC, atrioventricular canal; DILV, double-inlet left ventricle; D-TGA, dextrotransposition of the great arteries; RV, right ventricle; PA, pulmonary artery;
ECMO, extracorporeal membrane oxygenation; LSA, left subclavian artery. *Denominator ¼ number of survivors.
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dimensional analysis are detailed in Table 4.
Group A versus group B. The size of the neoaorta was
similar in both groups if ‘‘tube grafts’’ were used. Use of
cuff grafts resulted in larger neoaortic Z-scores in group BThe Journal of Thoracic and Caat pre–stage 2 cardiac catheterization (group A,
2.62  1.87 vs group B, 4.32  2.07; P ¼ .043). At pre–
stage 3 cardiac catheterization, the difference still existed
although was not significant (group A, 2.77 2.83 vs group
B, 4.57  1.33; P ¼ .106 [Table 4]).rdiovascular Surgery c Volume 146, Number 3 553
TABLE 2. Comparison of neoaortic coarctation by type of repair
Homograft tube Homograft cuff P value
Overall 24 (42%) 13 (46%) .82
Group A 19 (41%) 6 (46%) .76
Group B 5 (45%) 7 (47%) 1.00
FIGURE 2. Kaplan-Meier curve representing survival after Norwood
stage 1 operation. *Significant difference with use of circumferential fem-
oral vein homograft with end-to-side anastomosis of the ascending aorta.
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ameter of the ascending aorta as measured by absolute neo-
aortic diameter (Figure 3, A and B) was seen in both groups
with both technical modifications (tube grafts pre–stage 2
vs pre–stage 3: group A [10.61 mm  1.93 vs 13.74
mm  3.16; P<.001] and group B [13.93 mm  6.71 vs
17.38 mm  5.92; P ¼ .049] [Figure 3, A]; cuff repair pre–
stage 2 to pre–stage 3: group A [13.98 mm  2.13 vs 19.09
mm  4.18; P ¼ .002] and group B [16.06 mm  3.05 vs
19.73 mm  2.93; P<.001] [Figure 3, B]).
There was no change in the neoaortic Z-scores with time
in either group with either technical modification (tube
grafts pre–stage 2 vs pre–stage 3: group A (0.38  1.89
vs 0.00  2.08; P ¼ .42) and group B (1.76  4.60 vs
2.27  4.13; P ¼ .88) (Figure 3, C); cuff repair pre–stage
2 to pre–stage 3: group A (2.62  1.87 vs 2.77  2.83;
P ¼ .38) and group B (4.32  2.07 vs 4.57  1.33;
P ¼ .16) (Figure 3, D). The neoaortic Z-scores were gener-
ous with the use of homograft cuffs. When homograft tubes
were used the neoaorta was closer to normal size.
Cuffs versus tubes. Abnormal dilation of the neoaorta (Z-
score>2) was seen in both groups with the ‘‘cuff modifica-
tion.’’ Significantly higher neoaortic diameters and Z-scores
were seen for the ‘‘cuff technique’’ compared with the
‘‘tube grafts’’ at both pre–stage 2 and pre–stage 3 for group
A patients (pre–stage 2 diameter group A: cuff 13.98 2.13
vs tube 10.61  1.93; P<.001; pre–stage 2 Z scores group
A: cuff 2.62  1.87 vs tube 0.38  1.89; P<.001; pre–
stage 3 diameter: cuff 19.09  4.18; tube 13.74  3.16;TABLE 3. Predictors of mortality by multivariable Cox proportional
hazards regression
Variable P value
Hazard
ratio 95% CI
Age at stage 1, d .53 — —
Weight at stage 1 (<2.5 kg) .01* 3.7 1.7-7.8
Diagnosis (HLHS vs variant) .15 — —
Morphology (LV vs RV) .68 — —
Shunt (BT vs Sano) .08 — —
Repair type (cuff, tube, DB) .70 — —
ECMO after stage 1 <.001* 13.8 5.9-31.9
Ascending aorta diameter<2 mm .25 — —
Era of operation (2004-2011) .86 — —
Biomaterial (others vs FV) .01* 3.0 1.4-6.4
CI, Confidence interval; HLHS, hypoplastic left heart syndrome; LV, left ventricle;
RV, right ventricle; BT, Blalock-Taussig; DB, double-barrel; ECMO, extracorporeal
membrane oxygenation; FV, femoral vein. *Statistically significant predictor.
554 The Journal of Thoracic and Cardiovascular SurgP < .001; pre–stage 3 Z score: cuff 2.77  2.83; tube
0.00  2.08; P ¼ .008). A similar trend was noted in group
B but was not significant.
Neoaortic coarctation. Of the 85 survivors, 37 (44%) had
neoaortic coarctation as defined by need for balloon angio-
plasty and/or surgical arch augmentation. Similar neoaortic
coarctation rates were seen in both groups (A: 25/59
[42%]; B: 12/26 [46%]; P ¼ .81) (Table 1). There was
no difference in coarctation rate by type of repair (tube:
24/57 [42%]; cuff: 13/28 [46%]; P ¼ .82) (Table 2).
The narrowing was distal to the left subclavian artery in
89% (33/37; group A, 22; group B, 11) of patients with re-
coarctation. Ascending neoaortic narrowing was seen in 7
patients (group A, 5; group B, 2), all of whom had a cir-
cumferential tube homograft repair. Three patients had
narrowing of the neoaorta at both locations, albeit at sepa-
rate points in time.
Balloon angioplasty alone was required in 19 patients in
group A and 7 in group B. Poor response to balloon angio-
plasty led to surgical arch augmentation in 2 patients in
group A and 1 patient in group B. Location and nature of
the narrowing prompted direct operative aortic intervention
in 3 patients in group A and 4 in group B. Of the 5 patients in
group Awith ascending neoaortic narrowing, 3 had surgical
aortic augmentation, 1 had balloon angioplasty, and 1 re-
quired surgical aortic augmentation after angioplasty;
both the patients in group B with ascending neoaortic nar-
rowing underwent surgical aortic augmentation. Of all pa-
tients with ascending neoaortic narrowing, 2 patients in
group A and 1 in group B also had additional neoaortic co-
arctation distal to the left subclavian artery successfully
treated with balloon angioplasty at the pre–stage 2 cardiac
catheterization. Multivariable analysis confirmed that diag-
nosis of HLHS was the only significant predictor of coarc-
tation of the neoaorta (P ¼ .008).ery c September 2013
TABLE 4. Predictors of mortality by ascending aorta size and Z scores for patients who underwent the Norwood procedure with femoral vein and
other homografts stratified by repair type
Pre-Glenn cath
Femoral vein (group A) Other homografts (group B)
P valueMean ± SD n Mean ± SD n
Tube or double-barrel
Neoaorta, mm 10.61  1.93y 39 13.93  6.71 7 .240
Z-score 0.38  1.89y 39 1.76  4.60 7 .268
Cuff repair
Neoaorta, mm 13.98  2.13 11 16.06  3.05 14 .067
Z-score 2.62  1.87 11 4.32  2.07 14 .043*
Pre-Fontan cath Mean ± SD n Mean ± SD n P value
Tube or double-barrel
Neoaorta, mm 13.74  3.16y 19 17.38  5.92 6 .200
Z-score 0.00  2.08y 18 2.27  4.13 6 .246
Cuff repair
Neoaorta, mm 19.09  4.18 9 19.73  2.93 12 .683
Z-score 2.77  2.83 9 4.57  1.33 12 .106
SD, Standard deviation. *Statistically significant, Student t test. yStatistically significant difference between tube or double-barrel versus cuff repair in the femoral vein group
(P<.01). No significant differences between tube or double-barrel versus cuff repair among other homografts.
FIGURE 3. Neoaortic sizewith follow-up. Absolute neoaortic diameter in millimeters by type of repair. A, Circumferential tube homograft with or without
end-to-side ascending aortic anastomosis: Femoral vein homografts (group A) vs others (group B). B, Homograft cuff: Femoral vein homografts (group A)
vs others (group B). Neoaortic Z scores. C, Circumferential tube homograft with or without end-to-side ascending aortic anastomosis: Femoral vein homo-
grafts (group A) vs others (group B). D, Homograft cuff: Femoral vein homografts (group A) vs others (group B). BDG, Bidirectional Glenn.
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DDISCUSSION
The use of femoral vein homograft offers several advan-
tages for neoaortic reconstruction in theNorwood stage 1 op-
eration. Inasmuch as cryopreserved femoral vein homografts
are harvested from adult donors, they are widely available
compared with pediatric aortic or pulmonary homografts.
In addition to its lower cost, femoral vein homograft is sup-
plied as 20- to 30-cm long segments tapering from15 to 16 to
10 to 11mm in diameter, allowing intraoperative selection of
optimum-sized segment. The femoral vein tissue is thin
walled, thus being particularly suitable for end-to-side reim-
plantation of a particularly diminutive ascending aorta, thus
greatly simplifying this technically challenging operation.
Despite its thinness, the tissue is strong and hemostatic.4
The femoral vein also offers the versatility of being used
as a ‘‘homograft cuff’’ in a standard stage 1 Norwood oper-
ation when the ascending aorta is not diminutive, or for use
as a ‘‘tube graft without end-to-side anastomosis of the as-
cending aorta (double-barrel technique)’’ for HLHS variants
with a nearly normal sized ascending aorta.
In this study the use of femoral vein homograft was a neg-
ative predictor of mortality, with significant survival benefit
in the higher risk patients with diminutive ascending aorta
(<2 mm) when used as a tube graft with end-to-side ascend-
ing aortic reimplantation. Our findings of weight less than
2.5 kg at stage 1 and need for ECMO in the immediate post-
operative period being predictive of mortality are consistent
with previous reports.9,10 The characteristics of the groups
were similar with regard to prematurity, weight less than
2.5 kg, presence of intact/restrictive atrial septum,
prevalence of a diminutive ascending aorta, and need for
postoperative ECMO. No correlation between date of
stage 1 operation (era effect) and mortality was found
across the entire study period.
There was no difference in the rate of neoaortic coarcta-
tion evident between biomaterials used or between types of
repair. In an attempt to focus on late aortic arch obstruction,
we excluded operative mortalities from the neoaortic coarc-
tation analysis. Additionally, strict definition of recoarcta-
tion and low threshold for intervention may overestimate
the overall neocoarctation rates in this study. Nonetheless,
the similar rates of neoaortic recoarctation between groups
suggest that femoral vein homograft imparts no greater risk
of recoarctation than standard biomaterials.
Although there are growing concerns with severely di-
lated neoaortas after the stage 1 Norwood operation with
the standard cuff technique, the use of tube grafts has
a risk of subsequent neoaortic stenosis owing to their lack
of growth potential. It is reassuring in this study that the
use of homograft tubes did not lead to higher rates of neo-
aortic stenosis than did the cuff grafts. On the other hand,
an interesting progressive increase in the neoaortic size
was seen commensurate with somatic growth. In fact, the556 The Journal of Thoracic and Cardiovascular Surgneoaortic Z-scores were maintained in the modestly dilated
range. This could be due to dilation of the homograft with
time, especially with femoral vein homografts, supple-
mented by the growth potential of the incorporated ascend-
ing aorta. Technical modifications such as making the
end-to-side aortic reimplantation as long as possible limits
the rim of nongrowing circumference to a few millimeters
at the proximal and distal homograft tube anastomotic sites
only, with the majority of the homograft circumference still
left with growth potential.
This report has the limitation of being a single-center, ret-
rospective study with a limited number of patients and
short- to intermediate-term follow-up. Greater longitudinal
follow-up is needed to determine the long-term outcomes of
these patients. However, this is the only report of an attrac-
tive alternative biomaterial and technique for neoaortic re-
construction for the stage 1 Norwood operation.
CONCLUSIONS
Survivals are improved with the use of the femoral vein
homograft for neoaortic reconstruction for the Norwood
stage 1 operation, especially when used as a homograft
tube with end-to-side aortic reimplantation. Femoral vein
homografts have recoarctation rates similar to those of stan-
dard biomaterials. With appropriate technical modifica-
tions, homograft tube grafts and homograft cuffs have
similar recoarctation rates. Progressive growth/dilation of
the neoaorta in proportion to somatic growth is seen with
femoral vein tube grafts. The cryopreserved femoral vein
homograft is an excellent alternative biomaterial for neo-
aortic reconstruction in the Norwood stage 1 operation.
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